Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis

References

• Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep. 2016. doi:10.1016/j.lrr.2016.06.001
   Google Scholar
• Levin-Epstein R, Oliai C, Schiller G. Allogeneic hematopoietic stem cell transplantation for older patients with acute myeloid leukemia. Curr Treat Options Oncol. 2018. doi:10.1007/s11864-018-0577-2
   PubMed Web of Science ®Google Scholar
• Krug U, Büchner T, Berdel WE, et al. The treatment of elderly patients with acute myeloid leukemia. Dtsch Arztebl Int. 2011. doi:10.3238/arztebl.2011.0863
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015. doi:10.1182/blood-2015-01-621664
   Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012. doi:10.1200/JCO.2011.38.9429
   Google Scholar
• Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discovery. 2008. doi:10.1038/nrd2658
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016. doi:10.1158/2159-8290.CD-16-0313
   Web of Science ®Google Scholar
• Ram R, Amit O, Zuckerman T, et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann Hematol. 2019. doi:10.1007/s00277-019-03719-6
   Web of Science ®Google Scholar
• Aldoss I, Yang D, Pillai R, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol. 2019. doi:10.1002/ajh.25567
   Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018. doi:10.1016/S1470-2045(18)30010-X
   Web of Science ®Google Scholar
• DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukemia: a single-center, phase 2 trial. Lancet Haematol. 2020. doi:10.1016/S2352-3026(20)30210-6
   Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020: 1), doi:10.1056/NEJMoa2012971
   Web of Science ®Google Scholar
• Wei AH, Strickland SA, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019. doi:10.1200/JCO.18.01600
   Google Scholar
• Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009. doi:10.1371/journal.pmed.1000097
   Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. Br Med J. 2011. doi:10.1136/bmj.d5928
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J. 2003. doi:10.1136/bmj.327.7414.557
   Google Scholar
• Wei AH, Panayiotidis P, Montesinos P, et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood Cancer J. 2021. doi:10.1038/s41408-021-00555-8
   Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020. doi:10.1056/NEJMoa2012971
   Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019. doi:10.1182/blood-2018-08-868752
   Google Scholar
• Yamamoto K, Shinagawa A, DiNardo CD, et al. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol. 2022. doi:10.1093/jjco/hyab170
   Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020. doi:10.1182/blood.2020004856
   Google Scholar
• Yamauchi T, Yoshida C, Usuki K, et al. Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy. Jpn J Clin Oncol. 2021. doi:10.1093/jjco/hyab112
   Web of Science ®Google Scholar
• Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long-term follow-up from a phase 1b study. Am J Hematol. 2021. doi:10.1002/ajh.26039
   Web of Science ®Google Scholar
• Hu Y, Jin J, Zhang Y, et al. Zhonghua xueyexue zazhi. 2021. doi:10.3760/cma.j.issn.0253-2727.2021.04.004
   Google Scholar
• Ji J, Chen M, Han B. Comparison of hypomethylator monotherapy with hypomethylator plus chemotherapy for intermediate/high-risk MDS or AML: A meta-analysis. J Cancer. 2020. doi:10.7150/jca.40614
   Web of Science ®Google Scholar
• Kadia TM, Ravandi F, Borthakur G, et al. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021. doi:10.1002/ajh.26206
   Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006. doi:10.1002/cncr.21723
   Google Scholar
• Colunga-Lozano LE, Kenji Nampo F, Agarwal A, et al. Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis. PLoS One. 2022. doi:10.1371/journal.pone.0263240
   Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016. doi:10.1056/NEJMoa1513257
   Web of Science ®Google Scholar
• Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007. doi:10.1038/sj.onc.1210220
   Web of Science ®Google Scholar
• Pan R, Ruvolo VR, Wei J, et al. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015. doi:10.1182/blood-2014-10-604975
   Google Scholar
• Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014. doi:10.1158/2159-8290.CD-13-0609
   Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi:10.1038/nm.3048
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–778. doi:10.1016/S1470-2045(16)30019-5
   PubMed Web of Science ®Google Scholar
• Tsao T, Shi Y, Kornblau S, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012. doi:10.1007/s00277-012-1537-8
   PubMed Web of Science ®Google Scholar
• Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017. doi:10.1080/10428194.2017.1283032
   Web of Science ®Google Scholar
• Bogenberger JM, Delman D, Hansen N, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015. doi:10.3109/10428194.2014.910657
   PubMed Web of Science ®Google Scholar
• Gao C, Wang J, Li Y, et al. Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis. Medicine (Baltimore). 2018. doi:10.1097/MD.0000000000011860
   Web of Science ®Google Scholar
• Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019. doi:10.1038/s41375-019-0612-8
   PubMedGoogle Scholar
• DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020. doi:10.1182/blood.2019001239
   Google Scholar
• Döhner H, Wei AH, Roboz GJ, et al. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. 2022;140(15):1674–1685. doi:10.1182/blood.2022016293
   PubMed Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020. doi:10.1182/blood.2020004856
   Google Scholar
• Qin Y, Kuang P, Liu T. Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis. Clin Exp Med. 2022. doi:10.1007/s10238-021-00784-y
   Web of Science ®Google Scholar
• Agarwal SK, DiNardo CD, Potluri J, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39(2):359–367. doi:10.1016/j.clinthera.2017.01.003
   PubMed Web of Science ®Google Scholar